

1st Swedish National Conference on Advanced Therapy Medicinal Products

Medicon Village Science Park, Lund

March 15, 2018, 9 am to 6 pm

Welcome to a Swedish ATMP national conference!

Centre for Advanced Medical Products (CAMP), Swelife and Medicon Village cordially invites you to the first Swedish national conference on Advanced Therapy Medicinal Products (ATMP).

Who should attend? Students, academic researchers, health care representatives, industry and other stakeholders active in the ATMP area and interested in learning about advances in the Swedish ATMP scene and sharing their knowledge and experiences.

And why? This conference will provide insights into ongoing academic research, clinical applications and industrial activities in the field. Take the chance to meet potential collaborators and learn more about national initiatives around ATMP!

Organized by:

Centre for Advanced Medical Products (CAMP) is a Swedish national centre for research, clinical applications, production and commercialization of advanced therapies, for the benefit of patients and industrial growth.

Swelife-ATMP is a project aiming at strengthening Sweden's competitiveness within advanced therapies.

[Read more \(in Swedish\)](#)

Medicon Village is a science park offering a unique environment for life science, integrating research, innovation and enterprise to create value for human health and wellbeing. [Read more](#)

Organizing committee

Jukka Lausmaa, RISE Research Institutes of Sweden

Kristina Kannisto, Karolinska Universitetssjukhuset

Ann Novotny, Gothia Forum

Kerstin Jakobsson, Medicon Village Science Park



Program

09.00 **Registration and Coffee**

10.00 **Welcome and Introduction (Moderator: Mikael Wiberg)**

Welcome address

Kerstin Jakobsson, Executive Vice President, Medicon Village Science Park
Peter Nordström, Programme Director, Swelife

Introduction to Centre for Advanced Medical Products (CAMP)

Mikael Wiberg, Chairman, Centre for Advanced Medical Products

10.15 **Keynote Lecture**

Engineering Industrial Scale Manufacture of ATMPs in a Small Academic GMP Facility

Mark Lowdell, Director of Centre for Cell, Gene & Tissue Therapeutics,
Royal Free Hospital, Professor of Cell & Tissue Therapy, University College
London, United Kingdom

10.45 **Translational ATMP projects in Sweden (Chair: Anders Lindahl)**

10.45 *CD19 Targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy*
Gunilla Enblad, Professor, Uppsala University

11.05 *Adoptive T Cell Transfer Combined with DC Vaccination in Patients with Metastatic Melanoma*

Stina Wickström, Postdoctoral Researcher, Karolinska Institutet

11.20 *Natural Killer Cell-based Immunotherapy for High-risk Myeloid Diseases*

Andreas Björklund, Assistant Professor, Karolinska Institutet

11.35 *Stem Cells, no Longer Lost in Translation*

Malin Parmar, Professor, Lund University

11.50 *Establishment of GMP Embryonic Stem Cells for the Use in Regenerative Medicine*

Fredrik Lanner, Assistant Professor, Karolinska Institutet

12.00 **Lunch**

13.00 **Translational ATMP Projects in Sweden, continued (Chair: Pontus Blomberg)**

13.00 *Keratinocytes in Burn Care, an ATMP: Past, Present and Future*
Alexandra Karström, Uppsala University Hospital

13.15 *Reconstructed Tissues for Female Fertility Treatments*

Mats Hellström, Assistant Professor, University of Gothenburg

13.30 *Boost Brittle Bones before Birth (BOOSTB4)*

Cecilia Götherström, Associate Professor, Karolinska Institutet

13.45 *From Cultured Cells to ATMP in Cartilage Regeneration*

Anders Lindahl, Professor, University of Gothenburg

- 14.00 **Short Break**
- 14.10 **Commercialization of ATMP in Sweden (Chair: Agneta Edberg)**
- 14.10 *AstraZeneca R&D in Cell and Gene Therapy*
Anna Sandström, Science Policy and Relations Director Europe, AstraZeneca
- 14.20 *Epithelial Cell Sheets for Esophageal Regeneration*
Camilla Huse Bondesson, Country Manager, CellSeed Sweden AB
- 14.30 *Development of Tolerogenic Cell Therapy using Dendritic Cells*
Anette Sundstedt, Chief Scientific Officer, Idogen AB
- 14.40 *Mesenchymal Stem Cells in Clinical Trial for Treatment of Autoimmune Disease*
Mathias Svahn, Chief Executive Officer, NextCell Pharma AB
- 14.50 *Challenges when Introducing Cell and Gene Therapies*
Emmelie Persson, Head Market Access & External Affairs,
Novartis Oncology Sweden
- 15.00 *Gene Therapy - A Potential Game Changer: Opportunities and Threats*
Christoph Varenhorst, Country Medical Director, Pfizer Sweden
- 15.10 *Personalized Tissue Engineered Grafts – A Specialty within a Specialty Area*
Raimund Strehl, Chief Technology Officer, VeriGraft AB
- 15.20 *Developing and Producing MSCs for the Prevention and Treatment of Cartilage Disease*
Evy Lundgren-Åkerlund, Chief Executive Officer, Xintela AB
- 15.30 **Break and Refreshments**
- 16.00 **Presentation of Swedish ATMP Initiatives and Panel Discussion (in Swedish):**
- Presentation av initiativ för att stärka utvecklingen av ATMP i Sverige:
Centre for Advanced Medical Products och Swelife-ATMP*
Mikael Wiberg, Kristina Kannisto, Ann Novotny
- Paneldiskussion: Hur kan vi få igång en starkare ATMP-utveckling i Sverige?*
Mikael Wiberg, Alexandra Karström, Anders Lindahl, Johan Hyllner, Anna Sandström, Agneta Edberg + publik
- 17.00 **Concluding Remarks**
- 17.10 **Networking and Refreshments**
- 18.00 **End of Conference**

We thank our sponsors



Centre for Advanced Medical Products (CAMP) and Swelife-ATMP are national projects funded by the Swedish National Innovation Agency VINNOVA

